Compare Ishares Msci Italy ETF (EWI) vs Summit Therapeutics Inc (SMMT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Ishares Msci Italy ETF vs Summit Therapeutics Inc — how do they compare? Ishares Msci Italy ETF trades at $60.54, while Summit Therapeutics Inc trades at $14.15 (market cap $11.70B). The key difference: Ishares Msci Italy ETF is trading nearer its 52-week high, Summit Therapeutics Inc nearer its low. Which is the better fit depends on your goals.
| EWI | SMMT | |
|---|---|---|
Sector | Broad Market / Factor | Health |
52-Week High | $61.14 | $29.32 |
52-Week Low | $47.75 | $13.05 |
Market Cap | — | $11.70B |
Enterprise Value | — | $11.12B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
Summit Therapeutics (SMMT) trades at $14.51, down 6.21% today, with a bearish technical outlook despite positive clinical trial results for its lung cancer drug ivonescimab. The company reported a net loss of $1.08 billion in 2025, with negative ROE and ROA, but maintains strong analyst support with 14 buy ratings and a $15.57 consensus price target. Recent developments include the $105 million divestiture of ridinilazole to Biossil and upcoming Q2 2026 earnings.
SMMT presents a high-risk, binary investment case centered on ivonescimab's commercial potential. While analyst sentiment is bullish and recent trial data is promising, the company's significant losses, cash burn, and single-asset focus pose substantial risks. The stock's volatility and concentrated ownership create potential for sharp moves around clinical and regulatory catalysts.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Ishares Msci Italy ETF
EWI is a country-specific ETF that tracks the performance of the Italian equity market. It provides targeted access to large and mid-sized companies in Italy, with a heavy focus on the financial sector and holdings like UniCredit and Intesa Sanpaolo.
Read more on EWI →About Summit Therapeutics Inc
Summit Therapeutics Inc. is a biopharmaceutical company focused on the development and commercialization of new medicines for the treatment of infectious diseases and other unmet medical needs. The company's lead product candidate is an antibiotic for the treatment of Clostridioides difficile infection (CDI), a serious infection of the colon. Summit Therapeutics is committed to bringing innovative therapies to market to address global health challenges and improve patient outcomes.
Read more on SMMT →
